You are currently here:

You are here

 

You are here

Biology into medicine

Taking our cue from the body's own mechanisms

Extended basic page

Explore other content within Oncology  

Block before Body

Our pillars of research

Pfizer's Oncology Research Unit (ORU) strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients.
The ORU comprises four pillars: Tumor Cell Biology, Bioconjugates Discovery and Development, Precision Medicine, and Integrative Biology and Biochemistry.

Blocks after Body

Pfizer Scientist Bob Abraham Meets Patient Matt Hiznay

Cancer researcher Bob Abraham and his team develop drugs to help treat cancer patients like Matt Hiznay. Now Matt is studying for his PhD so he can be just like the guy who helped save his life.

We aim to kill cancer cells

At Pfizer Oncology, a key technology focus is advancing the next wave of antibody-drug conjugates, which are targeted therapies that combine the specificity of an antibody with the cancer cell–killing power of a chemotherapy.

Working toward the next breakthrough

Cancer is not a singular disease and neither is our approach to treating it. Whether it’s simultaneously investigating multiple mechanisms of action or initiating collaborations with the brightest minds in the private and public sectors, Pfizer is committed to doing what it takes to overcome this devastating disease.
— Mikael Dolsten, MD, PhD
President of Worldwide R&D

We're working to restore cell-cycle control

In some cancers, increased activity of cyclin-dependent kinases (CDKs) may result in a failure to regulate cell proliferation. Pfizer scientists are investigating how inhibition of CDK activity may help reduce cell proliferation.